Pain management solution from Promex and Realeve honored by MedTech Breakthrough Awards
Pulsante, a pioneering pain management solution, is making waves in the medical field. This drug-free, safe, and effective treatment option is designed to improve the lives of patients suffering from conditions such as chronic migraine, neuropathic pain, and even sleep disorders and anxiety [1].
The innovative device, developed by Realeve and Promex, is the first externally powered implantable neuromodulation device system for treating central nervous system (CNS) disorders. This technological breakthrough eliminates the need for internal batteries, reducing the size of the implant and potentially lowering the risks associated with battery depletion or replacement surgeries [1].
Dr. Peter Bonutti, founder and CEO of Realeve, has over 30 years of experience in the medical field and has more than 500 patents to his name. His latest creation, Pulsante, is no exception. The system, clinically proven in over 700 patients and boasting FDA Breakthrough Device designation, has shown significant promise in treating conditions linked to nerve dysfunction [1].
In studies of chronic cluster headaches, 75% of participants reported a significant reduction in headache frequency and intensity using the system over a four-week period [1]. Pulsante offers patients greater independence and improves healthcare delivery by reducing reliance on medications and the need for clinic visits [1].
Dave Fromm, chief operations officer at Promex, highlighted the advantage of Pulsante as an alternative to traditional, more invasive therapies. He stated that the compact and wearable device delivers precise electrical pulses to the nervous system, making it a less intrusive option [1].
The Pulsante RC-200 handheld device powers the implant and has the potential to treat a range of brain-related conditions. The system's precision aims to improve patient outcomes, offering more targeted treatment [1].
MedTech Breakthrough, an independent market intelligence organisation, recognised Promex and Realeve for their innovation and success. The duo was awarded the 2025 Best New Pain Management Technology Solution for Realeve's Pulsante [1]. This recognition underscores Pulsante's impact as a pioneering advancement in neuroprosthetics and pain management technologies.
While detailed technical specifics or clinical trial outcomes are not widely available, Pulsante's recognition by MedTech Breakthrough highlights its potential as a game-changer in the field of pain management. Future iterations of Pulsante may incorporate AI-based pain tracking and predictive analytics, further enhancing its capabilities [1].
In summary, Pulsante is a promising development in the realm of pain management. Its externally powered, implantable neuromodulation device system offers a novel approach to pain management, potentially improving safety, device longevity, and patient comfort compared to traditional battery-powered implants. With its potential for treating a range of brain-related conditions and its recognition as the 2025 Best New Pain Management Technology Solution, Pulsante is set to revolutionize the field of pain management.
[1] Sources: Promex, Realeve, MedTech Breakthrough Awards.
- The field of digital health is witnessing a revolution with Pulsante, a pioneering pain management solution, which is designed to treat not only chronic migraine and neuropathic pain, but also sleep disorders and anxiety.
- This innovation in health-and-wellness, developed by Realeve and Promex, is a technological breakthrough that eliminates the need for internal batteries in implants, potentially lowering risks associated with battery depletion or replacement surgeries.
- Fitness-and-exercise and overall health may also be benefited as Pulsante, clinically proven in over 700 patients, offers a less intrusive option compared to traditional therapies, delivering precise electrical pulses to the nervous system.
- In the future, therapies-and-treatments for neurological-disorders such as chronic cluster headaches may further improve with AI-based pain tracking and predictive analytics integrated into Pulsante, a soon-to-be-game-changer in the realm of pain management technologies, as recognized by MedTech Breakthrough Awards.
